SIGA Technologies, Inc.
SIGA Technologies, Inc. (Nasdaq: SIGA) is a commercial-stage pharmaceutical company that sells TPOXX®, an antiviral treatment for smallpox, to the U.S. and international governments and government-affiliated entities. Its products include oral TPOXX and an intravenous formulation; oral TPOXX is also marketed in… From the company’s description.
Over the twelve months to Jun 30, 2026, SIGA Technologies, Inc. reported revenue of $53.66M, down 70.1% from a year earlier, and a net loss of $2.79M. Its operating margin was −20.8%, and operations used $20.17M in cash. In fiscal 2025, it reported revenue of $94.57M, down 31.8% from fiscal 2024, and net income of $23.28M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What SIGA Technologies, Inc. does
In the company’s own words
SIGA Technologies, Inc. (Nasdaq: SIGA) is a commercial-stage pharmaceutical company that sells TPOXX®, an antiviral treatment for smallpox, to the U.S. and international governments and government-affiliated entities. Its products include oral TPOXX and an intravenous formulation; oral TPOXX is also marketed in certain countries as Tecovirimat-SIGA or TEPOXX. The company’s principal customers are public health and defense agencies, with sales also possible to other government and healthcare customers. SIGA has no reportable business segments described here and relies on contract manufacturers to produce its products rather than operating its own manufacturing infrastructure. It has delivered oral TPOXX to the U.S. Strategic National Stockpile since 2013, including under a multiyear contract with the Biomedical Advanced Research and Development Authority that also covers IV product and related development and manufacturing activities. Oral TPOXX has regulatory approvals in the United States, Europe, Canada, the United Kingdom and Japan. SIGA had 49 full-time employees as of February 13, 2026.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEW YORK, NY
- Fiscal year end
- December
- CIK
- 1010086
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns SIGA Technologies, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · SIGA Technologies, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do SIGA Technologies, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of SIGA Technologies, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in SIGA Technologies, Inc.'s last four quarterly filings that the numbers alone won't show?”